A novel tumor necrosis factor-a inhibitory protein, TIP-B1

TIP-B1, a novel TNF inhibitory protein, has been identified, purified and characterized from cytosolic extracts of TNF-treated human fibroblasts, and a partial TIP-B1 cDNA clone has been obtained. The (27 kDa pI 4.5 TIP-B1 protein is unique based on both the sequence of three internal peptides (comprising 51 amino acids), and the nucleotide sequence of the corresponding cDNA clone. TNF-sensitive cells, when exposed to TIP-B1 prior to the addition of TNF, are completely protected from TNF-induced lysis. Thus, this TIP-B1 treatment effectively makes these cells TNF-resistant. Furthermore, TIP-B1 protects cells from apoptotic lysis induced by TNF. TIP-B1 does not interfere with the interactions between TNF and the TNF receptors based on flow cytometric analysis of the cellular binding of biotinylated TNF. These and other data indicate that TIP-B1 is not a soluble TNF receptor, nor an anti-TNF antibody, nor a protease that degrades TNF, yet TIP-BI functions when added exogenously to cells. Thus, TIP-B1 is not one of the proteins previously reported to be involved in resistance to TNF. The fact that incubation of the newly discovered novel TIP-B1 with TNF-sensitive cells protects them from TNF-induced cell death, including TNF-mediated apoptosis, makes TIP-B1 a candidate for therapeutic modulation of TNF-induced effects.

[1]  M. J. Ehrke,et al.  Role of tumor necrosis factor in macrophage activation and tumoricidal activity. , 1988, Cancer research.

[2]  M. Jäättelä,et al.  Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. , 1992, The EMBO journal.

[3]  M. J. Ehrke,et al.  TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells. , 1994, Lymphokine and cytokine research.

[4]  L. Owen-Schaub,et al.  DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. , 1992, Cellular immunology.

[5]  D. Kramer,et al.  Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. , 1999, Cancer research.

[6]  V. Dixit,et al.  The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. , 1992, The Journal of biological chemistry.

[7]  D. Goeddel,et al.  Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism , 1988, Science.

[8]  M. Jäättelä,et al.  Heat-shock proteins protect cells from monocyte cytotoxicity: possible mechanism of self-protection , 1993, The Journal of experimental medicine.

[9]  M. J. Ehrke,et al.  Protective specific immunity induced by doxorubicin plus TNF‐α combination treatment of EL4 lymphoma–bearing C57BL/6 mice , 2000, International journal of cancer.

[10]  L. Gooding,et al.  Sensitivity to tumour necrosis factor-mediated cytolysis is unrelated to manganous superoxide dismutase messenger RNA levels among transformed mouse fibroblasts. , 1991, Immunology.

[11]  M. J. Ehrke,et al.  Cyclophosphamide plus tumor necrosis factor‐α chemoimmunotherapy cured mice: Life‐long immunity and rejection of re‐implanted primary lymphoma , 1995, International journal of cancer.

[12]  M. J. Ehrke,et al.  Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. , 1992, Cancer research.

[13]  M. J. Ehrke,et al.  Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. , 1999, Cancer research.

[14]  A. Bollon,et al.  Tumor necrosis factor activities and cancer therapy--a perspective. , 1993, Pharmacology & therapeutics.

[15]  J. Melendez,et al.  Reduced expression of manganese superoxide dismutase in cells resistant to cytolysis by tumor necrosis factor. , 1992, Free radical biology & medicine.

[16]  M. J. Ehrke,et al.  Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activity. , 1987, Cancer research.

[17]  C. Baglioni,et al.  Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. , 1991, The Journal of biological chemistry.

[18]  M. J. Ehrke,et al.  Doxorubicin plus tumor necrosis factor α combination treatments in EL4-lymphoma-bearing C57BL/6 mice , 1998, Cancer Immunology, Immunotherapy.

[19]  L. Old,et al.  Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor , 1986, The Journal of experimental medicine.

[20]  P. Mehlen,et al.  Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. , 1995, Journal of immunology.